Instrument Inactif

Communiqués Cortex Pharmaceuticals OTC Bulletin Board

Actions

US2205243007

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

19/11	RespireRx Pharmaceuticals annonce l'obtention d'une subvention du NIH/NINDS et la signature d'un accord de licence de brevet modifié	CI
20/03/24	RespireRx Pharmaceuticals Inc. annonce la publication de résultats de recherche préclinique démontrant la capacité du CX1739, sa principale AMPAkine clinique, à améliorer la fonction vésicale après une lésion de la moelle épinière.	CI

Communiqués

10/02/25	RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties	AQ
08/07/24	RespireRx Pharmaceuticals : Material Agreement Form 8 K	PU
29/05/24	RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury	AQ
20/03/24	RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury	AQ
13/02/24	RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine	AQ
22/01/24	RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors	AQ
04/01/24	RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient	AQ
11/12/23	RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development	AQ
12/10/23	RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services	AQ
02/10/23	RespireRx Pharmaceuticals : SETTLEMENT AND EXCHANGE AGREEMENT - Form 8-K	PU
09/08/23	RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company	AQ
13/06/23	RespireRx Pharmaceuticals : Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Plan - Form 8-K	PU
13/06/23	RESPIRERX PHARMACEUTICALS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
24/05/23	ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs	AQ
05/05/23	RESPIRERX PHARMACEUTICALS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
17/04/23	RESPIRERX PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
13/04/23	RespireRx Pharmaceuticals : EXCHANGE AGREEMENT - Form 8-K	PU
13/04/23	RESPIRERX PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
06/04/23	RespireRx Pharmaceuticals : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K	PU
06/04/23	RESPIRERX PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
05/04/23	RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders	AQ
04/04/23	RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation	AQ
03/04/23	RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.	AQ
28/03/23	RESPIRERX PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
28/03/23	RespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of Directors	AQ